
The Amazing Ways AI Agents Will Transform Healthcare
AI agents represent the next transformational wave in healthcare, moving beyond simple diagnosis ... More tools to autonomous systems that can schedule appointments, create detailed medical reports, and monitor patients remotely without human intervention.
Healthcare is already a hotbed of AI activity, which has more than proved its worth as a tool for diagnosing illness, monitoring recovery, and developing new medicines.
But globally, the industry is still grappling with longstanding challenges, including shortages of clinical staff, aging populations, and managing the front-loaded costs of transitioning to more preventative models of healthcare.
This is where AI agents, the next wave of AI transformation, will come in. Compared to existing AI (think of the current generation of language-based chatbots like ChatGPT), Agentic AI is capable of carrying out far more complex tasks with minimal human interaction.
To give a simple example, a non-agentic computer vision-based AI algorithm can be used to scan medical images and spot early warning signs of cancer.
An agentic AI, on the other hand, could cross-reference the images with other clinical patient data, create a detailed report for a doctor, and schedule a follow-up appointment, all without human involvement.
This switch from passive provider of information to active action-taking is what defines the newest generation of tools and applications driven by agentic AI.
Experts predict it will soon be just as transformational to healthcare as today's cutting-edge computer vision, chatbots and other AI innovations have proven to be. So here's an overview of how it may soon be put to work in hospitals, doctors' surgeries, and care homes near you.
Agentic Healthcare Intelligence
Several use cases for agentic applications have been identified in healthcare. Although most are currently theoretical, they give us an idea of how agents could surpass the capability of non-agentic tools and apps.
Automated triage and scheduling systems could relieve clinical and administrative staff of much of the burden of routine procedures and paperwork. Rather than simply asking patients to answer questions, it can use computer vision to carry out initial examinations and flag urgent cases for immediate help.
AI agents have also been built to assist with clinical decision-making. By augmenting large language models like GPT-4 with tools to understand MRI, CT and other medical data, one test found an agent could reach a correct diagnosis in 91% of cases.
They will also become increasingly useful in remote patient monitoring. Their ability to make more accurate decisions about when to intervene and how to protect patient privacy and security will mean more people can stay out of hospital and be treated at home.
Agents are even being put to use in clinical trials, carrying out tasks such as screening applications, matching candidates to trials and booking transportation to the test facility.
For non-clinical use, the AI health monitors we use on smartwatches and fitness bands will become much smarter and more proactive. Rather than simply measuring heart rate, skin temperature and so on, they'll be ready to give us a holistic overview of our health at any time and then monitor the action we take towards improving it.
Finally, agents will help complete administrative tasks more efficiently by automating decisions around scheduling, reading and replying to emails, and handling billing and commissioning. While this can be done by existing AI on a task-by-task basis, agents will take oversight of entire workflows or even business functions, reducing human error and time spent on routine work.
A great deal of academic research is currently taking place into how we can safely use and understand the impact of agentic AI in healthcare. Answering these questions will play a bit part in helping these use cases get off the ground.
What About The Risks?
With greater autonomy and the ability to interact with external systems, AI agents clearly introduce new risks that could be particularly dangerous in healthcare ecosystems.
Data security is an obvious one, and new security measures will be required to balance the need for agents to access personal data with the dangers this creates. Confidential patient information, as well as control over critical systems, could be at stake if agents are compromised by malicious individuals or groups or just don't work like they're supposed to.
Agents will also force healthcare service providers to answer questions and provide assurances about accountability. AI can't take responsibility for its actions, so how is it shared between the healthcare industry, AI developers, and the clinical staff and patients who use it?
Then there's the simple fact that AI is often wrong. Whether it's down to bad data or hallucination, it simply isn't right 100 percent of the time. Of course, neither are humans. So when is it right to hand over the reins?
And, of course, we're far from the point where anyone thinks it's right to let machines make decisions that affect humans without human oversight. So, how do we make sure that oversight is in place, effective and accountable?
Overcoming all of these challenges will be critical to safely integrating agentic AI into the healthcare system and unlocking the benefits it promises.
The Future Of Agents In Healthcare
By the end of the decade, we can expect agentic AI to have radically changed the way healthcare is delivered, managed and experienced.
Globally, healthcare has for some time understood the importance of moving from reactive to preventative care. Agents will proactively interact with wearables and home sensors to enable far earlier interventions when warning signs are detected.
This will happen within an agentic ecosystem, which delivers fully personalized care by fine-tuning treatment in response to patient data. Meanwhile, the workload of clinical professionals will involve far less time spent filling in forms or reviewing notes and more time using their uniquely human skills and experience to improve patient outcomes.
Access to healthcare in underserved areas could increase, with agents acting as gateways to telemedicine services, triaging initial contacts as well as freeing up human doctors to see more patients.
Of course, all of this depends on solving the challenges mentioned here. Once society understands the impact agents can have, there will be a demand for evidence that it can be trusted. By establishing where the boundaries lie as we build, test and use it today, we can lay the groundwork for a safe, agentic tomorrow.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Jim Cramer has a six-word response to upcoming bull market
Jim Cramer has a six-word response to upcoming bull market originally appeared on TheStreet. CNBC's Jim Cramer is well-known for his hot takes on the markets, which often draw sharp reactions from Crypto Twitter. It was no different this time, as he predicted $100 trillion coming into the market in an X post on June 27. Cramer warned traders, "Ignore this money at your own peril!" An X user asked Grok for more details on the post, to which the AI chatbot said Cramer's claim likely refers to $100 trillion worth of crypto market cap, with Bitcoin and Ethereum being main contributors. "This could mean market value, not new capital, as $100 trillion is close to global GDP ($115 trillion), making such an influx unlikely," Grok clarified. Join the discussion with CryptosRUs The CNBC host isn't the only analyst who is so bullish on crypto. Global Macro Investor's (GMI) head of macro research, Julien Bittel, recently shared what he called 'The Everything Code' on X, according to which the crypto market cap will hit $100 trillion over the next 7-10 years. The world is in the middle of a global race in which institutions, sovereigns, and individuals are accumulating as much Bitcoin as they can, Bitter underlined and added that the phenomenon will be the "driving force behind mass crypto adoption." He continued: "If we're right, this will be the single greatest wealth-creation opportunity of our lifetimes." To put things into perspective, the total crypto market cap stood at $3.26 trillion at the time of writing. The highest that the crypto market cap ever reached was $3.7 trillion around mid-December 2024. To meet the astronomical target of $100 trillion, the crypto market cap needs to grow more than 27 times. Jim Cramer has a six-word response to upcoming bull market first appeared on TheStreet on Jun 27, 2025 This story was originally reported by TheStreet on Jun 27, 2025, where it first appeared.
Yahoo
37 minutes ago
- Yahoo
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
What to Expect From Elevance Health's Q2 2025 Earnings Report
Valued at a market cap of $84.3 billion, Elevance Health, Inc. (ELV) is a managed healthcare company that offers a broad spectrum of health benefits and services, including medical, pharmacy, dental, vision, behavioral health, Medicare, and Medicaid plans. The Indianapolis, Indiana-based company is expected to announce its fiscal Q2 earnings for 2025 on Wednesday, Jul. 16. Prior to this event, analysts project this health insurance company to report a profit of $9.29 per share, down 8.2% from $10.12 per share in the year-ago quarter. The company has met or surpassed Wall Street's bottom-line estimates in three of the last four quarters, while missing on another occasion. Its earnings of $11.97 per share in the previous quarter aligned with the consensus estimates. Dear Nvidia Stock Fans, Watch This Event Today Closely Can Broadcom Stock Hit $400 in 2025? A $2 Billion Reason to Sell Super Micro Computer Stock Now Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For the full year, analysts expect ELV to report EPS of $34.42, up 4.2% from $33.04 in fiscal 2024. Furthermore, its EPS is expected to grow 13.8% year over year to $39.16 in fiscal 2026. Shares of Elevance Health have declined 30.2% over the past 52 weeks, considerably lagging behind both the S&P 500 Index's ($SPX) 12.1% uptick, and the Health Care Select Sector SPDR Fund's (XLV) 8.1% loss over the same time frame. On Apr. 22, shares of Elevance Health rose 2.3% as it delivered better-than-expected Q1 results. The company's operating revenue grew 15.4% year-over-year to $48.8 billion and surpassed the consensus estimates by almost 6%. Moreover, its adjusted EPS of $11.97 improved by 10.5% from the same period last year. This impressive performance was driven by higher premium yields in its health benefits segment, benefits from acquisitions completed in the past year, and strong growth in its CarelonRx product revenue. Ongoing cost management by the company further supported its profitability. Wall Street analysts are highly optimistic about ELV's stock, with a 'Strong Buy" rating overall. Among 20 analysts covering the stock, 15 recommend "Strong Buy," one suggests a 'Moderate Buy,' and four indicate 'Hold.' The mean price target for ELV is $492.94, which indicates a 32.1% potential upside from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data